Neil J Stone

  • 23181 Citations
1968 …2019
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

Lipid metabolism, cardiovascular nutrition; premature coronary heart disease

Certifications and Licenses

Internal Medicine
Cardiovascular Disease

Training Experience

1969Internship, Brigham & Women's Hospital
1970Residency, Brigham & Women's Hospital
1974Residency, Northwestern University, McGaw Medical Center (Northwestern Memorial Hospital)
1975Fellowship, Northwestern University, McGaw Medical Center (Northwestern Memorial Hospital)

Education/Academic qualification

MD, Northwestern University Feinberg School of Medicine

… → 1968


  • Cardiovascular Diseases
  • Lipid Disorders
  • Metabolism
  • Nutritional and Metabolic Diseases

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 16 Similar Profiles
Hydroxymethylglutaryl-CoA Reductase Inhibitors Medicine & Life Sciences
Cardiovascular Diseases Medicine & Life Sciences
Cholesterol Medicine & Life Sciences
Coronary Disease Medicine & Life Sciences
Guidelines Medicine & Life Sciences
LDL Cholesterol Medicine & Life Sciences
Primary Prevention Medicine & Life Sciences
Hyperlipidemias Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1968 2019

Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial

Virani, S. S., Akeroyd, J. M., Nambi, V., Michos, E. D., Morris, P. B., Nasir, K., Smith, S. C., Stone, N. J., Petersen, L. A. & Ballantyne, C. M., Jan 15 2019, In : Circulation. 139, 3, p. 410-412 3 p.

Research output: Contribution to journalLetter

Clinical Trials
Costs and Cost Analysis
Proprotein Convertase 9

Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons

Riestenberg, R. A., Furman, A., Cowen, A., Pawlowksi, A., Schneider, D., Lewis, A. A., Kelly, S., Taiwo, B. O., Achenbach, C. J., Palella Jr, F. J., Stone, N. J., Lloyd-Jones, D. M. & Feinstein, M. J., Mar 1 2019, In : American heart journal. 209, p. 79-87 9 p.

Research output: Contribution to journalArticle

Hydroxymethylglutaryl-CoA Reductase Inhibitors
HIV Infections
Cardiovascular Diseases

Treatment Gap in Primary Prevention Patients Presenting With Acute Coronary Syndrome

Bavishi, A., Howard, T., Kim, J. P., Hiramoto, B., Pierce, J. B., Mendapara, P., Alhalel, J., Wu, H. W., Srdanovich, N. & Stone, N. J., Feb 1 2019, In : American Journal of Cardiology. 123, 3, p. 368-374 7 p.

Research output: Contribution to journalArticle

Primary Prevention
Acute Coronary Syndrome
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Blood Pressure
American Heart Association
5 Citations

A Comparative Analysis of Current Lipid Treatment Guidelines: Nothing Stands Still

Tibrewala, A., Jivan, A., Oetgen, W. J. & Stone, N. J., Feb 20 2018, In : Journal of the American College of Cardiology. 71, 7, p. 794-799 6 p.

Research output: Contribution to journalReview article

Hydroxymethylglutaryl-CoA Reductase Inhibitors
United States Department of Veterans Affairs

A New HOPE? Lessons from Heart Outcomes Prevention Evaluation-3

Howard, T. M., Bavishi, A. A. & Stone, N. J., Feb 1 2018, In : American Journal of Medicine. 131, 2, p. 134-140 7 p.

Research output: Contribution to journalReview article

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cardiovascular Diseases
Randomized Controlled Trials
Group Psychotherapy